Sangamo Therapeutics Inc (SGMO)

NASDAQ
Currency in USD
1.1900
+0.0400(+3.48%)
Closed
After Hours
1.1800-0.0100(-0.8403%)
Fair Value
Day's Range
1.10501.2200
52 wk Range
0.30403.1790
Key Statistics
Edit
Prev. Close
1.15
Open
1.13
Day's Range
1.105-1.22
52 wk Range
0.304-3.179
Volume
2.69M
Average Volume (3m)
8.96M
1-Year Change
153.19%
Book Value / Share
0.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SGMO Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
5.5000
Upside
+362.18%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

Sangamo Therapeutics Inc Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Sangamo Therapeutics Inc SWOT Analysis


Genomic Frontiers
Sangamo Therapeutics advances gene therapy innovations, with partnerships in neurodegenerative diseases and promising results in hemophilia A treatment
Financial Tightrope
Extended cash runway to Q1 2025, but financial challenges persist. Analyst price targets range from $2 to $10, reflecting mixed market sentiment
Accelerated Horizons
Explore potential fast-track approval for Fabry disease treatment, positioning Sangamo for earlier market entry and competitive advantage
Strategic Alliances
Genentech partnership validates technology, provides funding, and opens doors to high-value neurodegenerative disease market, boosting long-term prospects
Read full SWOT analysis

Sangamo Therapeutics Inc Earnings Call Summary for Q3/2024

  • Sangamo aligns with FDA on Fabry disease program, potentially accelerating approval by 3 years; plans BLA submission with 1-year data by end of 2024
  • $50M milestone payment from Genentech received; hemophilia A program with Pfizer nearing regulatory submission, potential $220M in milestones
  • Phase III AFFINE trial for hemophilia A met primary endpoint; Sangamo to earn 14-20% royalties on sales
  • First IND for ST-503 (intractable pain) submitted; clinical trials expected mid-2025; company anticipates busy 2025 with potential BLA submissions
  • Positive patient feedback on Fabry treatment; potential product launch early 2026; FDA requests data from 32-patient cohort for approval
Last Updated: 13/11/2024, 10:22 pm
Read Full Transcript

Compare SGMO to Peers and Sector

Metrics to compare
SGMO
Peers
Sector
Relationship
P/E Ratio
−1.8x−2.3x−0.6x
PEG Ratio
−0.03−0.040.00
Price/Book
6.3x2.5x2.6x
Price / LTM Sales
4.7x6.0x3.1x
Upside (Analyst Target)
335.8%590.8%51.5%
Fair Value Upside
Unlock−12.2%7.6%Unlock

Analyst Ratings

5 Buy
3 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.5000
(+362.18% Upside)

Earnings

Latest Release
Nov 12, 2024
EPS / Forecast
0.04 / -0.02
Revenue / Forecast
49.41M / 20.92M
EPS Revisions
Last 90 days

People Also Watch

3.450
RR
+6.81%
2.410
QSI
+1.26%
1.610
HOLO
-3.01%
2.010
REKR
-3.37%
9.2500
PDYN
-2.73%

FAQ

What Is the Sangamo Therapeutics (SGMO) Stock Price Today?

The Sangamo Therapeutics stock price today is 1.19

What Stock Exchange Does Sangamo Therapeutics Trade On?

Sangamo Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Sangamo Therapeutics?

The stock symbol for Sangamo Therapeutics is "SGMO."

What Is the Sangamo Therapeutics Market Cap?

As of today, Sangamo Therapeutics market cap is 248.29M.

What is Sangamo Therapeutics Earnings Per Share?

The Sangamo Therapeutics EPS is -0.697.

What Is the Next Sangamo Therapeutics Earnings Date?

Sangamo Therapeutics will release its next earnings report on 18 Feb 2025.

From a Technical Analysis Perspective, Is SGMO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.